期刊文献+

异鼠李素抑制耐吉非替尼人肺癌细胞PC9增殖的研究 被引量:4

Isorhamnetin Suppresses the Growth of Gefitinib Resistant Human Lung Cancer PC9 Cells
下载PDF
导出
摘要 目的检测异鼠李素对耐吉非替尼的人肺癌细胞PC9增殖的影响。方法通过持续在人肺癌细胞系PC9的培养条件中加入吉非替尼培养直到PC9细胞出现耐药情况,即得到耐药细胞株(PC9-IR)。再将PC9-IR用不同浓度的异鼠李素处理,分别在24,48和72 h后用噻唑蓝(MTT)法检测细胞的生长情况,以正常人外周血单个核细胞(PBMNCs)作为对照组。同时采用蛋白质印迹法检测药物作用之后信号通路的变化,再用克隆分析检测isorhamentin对细胞克隆形成的影响。结果 MTT证实异鼠李素对PC9-IR的生长有明显的抑制作用,24,48,72 h的半数抑制浓度(IC50)分别为212,98,64μmol.L-1,而对PBMNCs72 h的IC50为204μmol.L-1,蛋白质印迹法证实isorhamnetin可以抑制Akt473位的磷酸化,克隆分析证实40μmol.L-1异鼠李素可明显抑制PC9-IR的克隆形成。结论异鼠李素对耐药的人肺癌细胞系(PC9-IR)的生长有抑制作用,可能因为抑制Akt473位的磷酸化水平。 Objective To investigate the role of isorhamnetin on the growth of PC9-IR cells. Methods The gefitinib-resistant PC9(PC9-1R) cells were generated by consistently culturing the PC9 cells with 10% FBS/DMEM contained 0.5 μmol· L^-1 gefitinib. Then, the PC9-IR cells were treated with isorhamnetin at different concentrations. The proliferation was detected by MTI" assay after 24,48 and 72 h, respectively, with PBMNCs as control. Western blot assay was used to detect the change of growth signal pathway. Additionally, clonal assay was performed to analyze the clone formation ability of PC9-IR with or without isorhamnetin. Results Isorhamnetin inhibitted the growth of PC9-IR. The ICso at the three time points were 212 μmol · L^-1 (24 h) ,98μmol· L^-1 1(48 h) ,64μmol· L^-1 (72 h) ,and PBMNCs was 204 μmol· L^-1 (72 h). It was showed that the phosph-Akt was suppressed and the clonal formation ability of PC9-IR was lowered by isorhamnetin. Conclusion Isorhmantin could inhibit the growth of PC9-IR cells through suppressing the phosphorylation of Akt.
出处 《医药导报》 CAS 北大核心 2012年第7期831-834,共4页 Herald of Medicine
基金 国家973计划(2009CB521802) 国家自然科学基金(30872472 30973496 30800569) 湖北省自然科学基金(2008CDB174 2009CDB239) 中央高校基本科研业务费专项资金(2011JC062 2011JC063) 华中科技大学自主创新基金(2010MS027)
关键词 异鼠李素 肺癌细胞 吉非替尼 耐药 Isorhamnetin Lung cancer cells Gefitinib Resistance
  • 相关文献

参考文献2

二级参考文献33

  • 1金小顺,耿小平,朱立新.肝癌多药耐药的研究进展[J].肝胆外科杂志,2007,15(3):234-236. 被引量:6
  • 2KRISHNA R,MAYER L D.Multidrug resistance (MDR) in cancer mechanisms,reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs[J].Eur J Pharm Sci,2000,11(4):265-283.
  • 3ABE K,MATSUKI N.Measurement of cellular 3-(4,5-di-methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction activity and lactate dehydrogenase release using MTT[J].Neurosci Res,2000,38(4):325-329.
  • 4CHAN J Y,SIU K P,FUNG K P.Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells[J].Cancer Lett,2006,236(2):250-258.
  • 5彭涛 刘晓波 田伏洲 等.MTT比色法中应采用分析纯二甲亚砜作为甲暨溶解剂.中国免疫学杂志,2000,4(15):39-40.
  • 6汪选斌,柯静,王家宁,黄永章,孔霞,郭凌郧,刘明,向继洲.三氧化二砷联合5-氟尿嘧啶对人大肠癌SW480细胞的抑制作用[J].郧阳医学院学报,2007,26(5):278-280. 被引量:4
  • 7Yang J,Shamji A,Matchacheep Set al.Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening. Chemistry and Biology . 2007
  • 8Grunwald V,DeGraffenried L,Russel Det al.Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Research . 2002
  • 9Strimpakos AS,Karapanagiotou EM,Saif MWet al.The role of mTOR in the management of solid tumors:an overview. Cancer Treatment Reviews . 2009
  • 10Wendel HG,De Stanchina E,Fridman JSet al.Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature . 2004

共引文献21

同被引文献35

引证文献4

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部